Five things for pharma marketers to know: Tuesday, May 22, 2018

Share this content:

Pennsylvania-based Geisinger Health System is offering DNA sequencing to 1,000 patients with the goal of looking for mutations in 77 genes with the hope of revealing medical conditions and examples of how treatments affect individuals. The health system hopes to expand the program to include all 3 million Geisinger patients. (Kaiser Health News)


Dova Pharmaceuticals has received FDA approval for its drug that treats low blood platelet count in patients with chronic liver disease. It can be used to decrease the need for platelet transfusions during medical procedures. The drug is the first treatment of its kind to be approved. (Reuters)


Celgene is investing $65 million more in Evotec to secure new cancer drugs. The partnership allows Celgene to pick up drugs from Evotec and for Evotec to continue research and development. (Endpoints)


Oscar Health is creating a model to provide fairer pay for doctors and give patients a better understanding of costs. The startup has created technology like iPhone apps for booking appointments and a system for processing insurance claims for a better member experience. (CNBC)


Celgene's business development head, George Golumbeski, has left the company. Golumbeski said the transition had been planned for two years. He has taken a position on the supervisory board for MorphoSys, as a scientific adviser at KSQ, and as a venture partner at ARCH. (Endpoints)


Share this content:
Scroll down to see the next article